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Beta-endorphin levels in both painful and 
painless diabetic peripheral neuropathy and 
its relations to pain characters and severity 
ABSTRACT
Introduction. In the peripheral nervous system (PNS), 
b-endorphins produce analgesia by binding to opioid 
receptors (particularly of the mu subtype) at both pre- 
and post-synaptic nerve terminals, primarily exerting 
their effect through presynaptic binding.
Aim was to study serum b-endorphin levels in diabetic 
patients with and without diabetic peripheral neuropa-
thy and its relations to characters and severity of pain 
in patients with painful diabetic peripheral neuropathy.
Material and methods. The study was a case control 
study including 88 participants; 73 diabetics and 15 
age and sex matched healthy subjects. For all subjects, 
levels of HbA1c, serum creatinine, total cholesterol, 
triglycerides, HDL and LDL as well as serum levels of 
b-endorphin were measured. Pain severity was de-
tected by using visual analogue pain scale.
Results. Serum b-endorphin shows no significant dif-
ference between diabetic neuropathic, diabetic non 
neuropathic and control groups (p = 0.275). Serum 
b-endorphin shows negative correlation with age 
(p = 0.049) and HbA1c (p = 0.048). While it was not cor-
related with pain severity (p = 0.371), NDS: total score 
(p = 0.803), BMI (p = 0.801), serum creatinine (p = 0.074) 
or DM duration (p = 0.607). Serum b-endorphin shows 
no significant difference between painful and painless 
neuropathy subgroups (p = 0.701). 
Conclusion. In our study serum b-endorphin levels 
showed no significant difference between patients 
with painless diabetic peripheral neuropathy and 
those with painful diabetic peripheral neuropathy with 
different characters of pain. Also, serum b-endorphin 
levels was not correlated with pain severity. (Clin Dia-
betol 2017; 6, 5: 159–171)
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Introduction
Diabetic peripheral neuropathy (DPN) is a com-
mon, distressing and debilitating complication that 
develops in up to 30–50% of diabetic patients. Distal 
symmetric polyneuropathy (DSP) is the commonest 
type of neuropathy complicating diabetes [1]. Pain is 
the most agonizing symptom of DPN [2].
The pathogenesis of DPN is not completely un-
derstood, however vascular and metabolic factors are 
incriminated [3]. 
Magnetic resonance imaging (MRI) detected 
shrinkage of the spinal cord in patients with DPN [4], 
and also dysregulations of the somatosensory afferent 
pathways, thalamic neuronal dysfunction, and perfu-
sion abnormalities, which reports a significant involve-
ment of the CNS in patients with DPN [3].
Beta-endorphins are neuropeptides that have mor-
phine like effects [5]. They are synthesized and stored 
in the anterior pituitary gland from their precursor 
protein ProOpioMelanoCortin (POMC), that is synthe-
sized in response to a signal from the hypothalamus; 
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which is corticotrophic-releasing hormone (CRH), 
released in response to physiologic stress as pain, and 
postoperative [6].
Beta-endorphins produce analgesia in the periph-
eral nervous system (PNS), by binding to opioid recep-
tors (particularly of the mu subtype) at both pre- and 
post-synaptic nerve terminals, resulting in inhibition 
of the release of tachykinins, particularly substance P, 
preventing the transmission of pain [7].
In the CNS, beta-endorphins similarly bind mu-
opioid receptors and exert their primary action at 
presynaptic nerve terminals, they exert their analgesic 
effect by inhibiting the release of gamma-aminobutyric 
acid (GABA), an inhibitory neurotransmitter, resulting in 
excess production of dopamine, which is associated with 
pleasure [8],and patients with chronic neuropathic pain 
were found to have low levels of b-endorphin in the cer-
ebrospinal fluid (CSF),which indicates a defective down 
modulation of pain in chronic neuropathic pain [9].
The aim of this work was to study serum b-endorphin 
levels in diabetic patients with and without diabetic 
peripheral neuropathy and to study the possible dif-
ferences between patients with painful and painless 
diabetic peripheral neuropathy. We also aimed to 
study serum b-endorphin levels relations to characters 
and severity of pain in patients with painful diabetic 
peripheral neuropathy.
Material and methods
The study included 88 participants, 73 of them 
were diabetics (cases) recruited from Mansoura Specia-
lized Medical Hospital (diabetes outpatient clinics) from 
February 2015 to December 2015, and 15 participants 
were age and sex matched healthy subjects (control 
group). Diabetic state was confirmed or excluded ac-
cording to the revised American Diabetes Association 
criteria [10]. Ethical approval was obtained and each 
subject gave a written informed consent. The patients 
were divided into three groups Group (1); 57 diabetic 
subject with DPN which were further subdivided into 
2 subgroups according to presence or abscence of 
pain. Visual analogue pain scale was used to assess 
the severity of pain. Group (2); 16 diabetic subjects 
without peripheral neuropathy. Group (3); control 
group consists of 15 healthy subjects.
Diagnosis of DPN was based on modified neuropa-
thy disability score. We use score ≥ 6 as a cut point 
for diagnosis of DPN. Presence of pain in the legs was 
known from history and its severity was graded accord-
ing to visual analogue pain scale. The following findings 
is considered as exclusion criteria: patients with serum 
creatinine > 1.4 mg/dL, liver cell failure, neuropathy due 
to causes other than diabetes mellitus, CNS disorders. 
HbA1c %, serum creatinine, total cholesterol, tri-
glycerides, HDL and LDL levels were measured. Serum 
b-endorphin was assayed by ELISA supplied by Elabsci-
ence (USA). The study design was case control study.
Statistical analysis
Data were tabulated, coded then analyzed using 
the computer program SPSS (Statistical package for social 
science) version 22.0 for Windows. Spearman correla-
tion coefficient® test was used correlating different 
parameters. P value < 0.05 was considered statistically 
significant in all analyses. 
Results
The study included 57 diabetic subjects with 
diabetic peripheral neuropathy, 16 diabetic subjects 
without peripheral nerve dysfunction and 15 healthy 
control subjects. 
The mean age of patients in the neuropathic group 
(53.91 ± 5.53 years) was not significantly different from 
either the diabetic or control groups (50.37 ± 7.56 and 
50.93 ± 5.65 years, respectively) (p = 0.053).
Male and female number and percentage ratio 
in the diabetic neuropathic group was 26 (45.6%)/31 
(54.4%), in the diabetic non neuropathic group 8 
(50%)/8 (50%) and in the control group 8 (53.3%)/7 
(46.7%) in male and feme respectively. The difference 
between all groups regarding gender was statistically 
insignificant (p = 0.850).
There was no significant difference between dia-
betic neuropathic, diabetic non neuropathic and control 
groups as regard body mass index (p = 0.489). BMI in the 
studied groups was [32.29 (28.1–38.3), 35.62 (27.675–
–40.8) and 31.88 (25.95–35.78) kg/m2, respectively].
Systolic BP wasn’t significantly different (p < 0.084) 
between diabetic neuropathic, diabetic non neuropa-
thic and control groups [130 (120–140), 120 (120–130) 
and 120 (110–130) mm Hg, respectively], also there 
was no significant difference regarding diastolic BP 
between the studied groups [80 (70–90), 70 (70–80) 
and 80 (70–80) mm Hg respectively] (p < 0.336).
All subjects of the control group were normoten-
sive, while most of the patients in the diabetic neu-
ropathic and diabetic non neuropathic groups were 
hypertensive. There were 40 hypertensive patients 
(70.2%) in the diabetic neuropathic group, and 9 pa-
tients (56.2%) in the diabetic non neuropathic group. 
There was no significant difference between the two 
groups regarding the number of patients with hyper-
tension (p = 0.295).The duration of hypertension was 
significantly longer in the diabetic neuropathic versus 
diabetic non neuropathic groups [5 (0–15) and 0.5 
(0–4) years respectively] (p < 0.001).
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Table 1. Demographic and clinical data of the studied groups
Data Groups p
Diabetic neuropathy 
present
Diabetic neuropathy 
absent
Control
Age (years) Mean 53.912 50.375 50.933 0.053
± SD 5.536 7.562 5.65
Gender (N/%) Male 26 (45.6%) 8 (50%) 8 (53.3%) 0.850
 Female 31 (54.4%) 8 (50%) 7 (46.7%)
BMI [kg/m2] Median 32.29 35.62 31.88 0.489 
Range 28.1–38.3 27.675–40.8 25.95–35.78
SBP [mm Hg] Median 130 120 120 0.084 
Range 120–140 120–130 110–130
DBP [mm Hg] Median 80 70 80 0.336
Range 70–90 70–80 70–80
Hypertension (N/%) Yes 40 (70.2%) 9 (56.2%) < 0.295
No 17 (29.8%) 7 (43.8%)
Hypertension duration 
(years)
Median 5 0.5 < 0.001
 Range 0–15 0–4
Hypertension treatment 
(N/%)
ACEIs 14 (24.6%) 6 (37.5%) 0.028
BBs 2 (3.5%) 1 (6.3%)
CCBs 3 (5.3%) 1 (6.3%)
Combination 21 (36.9%) 1 (6.3%)
No 17 (29.8%) 7 (43.8%)
DM duration (years) Median 14 4 < 0.001
Range 8.5–20 1.125–9.5
DM treatment (N/%) SU 8 (14%) 4 (25%) < 0.058
Insulin 11 (19.3%) 8 (50%)
Insulin + metformin 31 (54.4%) 0 (0%)
SU + metformin 7 (12.3%) 4 (25%)
P — probability; SD — standard deviation; BMI — body mass index; SBP — systolic blood pressure; DBP — diastolic blood pressure; ACEIs — angiotensine 
converting enzyme inhibitors; BBs — beta-blockers; CCBs — calcium channel blockers; SU — sulphonylurea
There was no significant difference between dia-
betic neuropathic and diabetic non neuropathic groups 
as regard the anti-hypertensive drugs (p = 0.028). In 
diabetic neuropathic and diabetic non neuropathic 
groups there were following number of patients re-
ceiving ACEIs: 14 (24.6%) and 6 (37.5%) respectively, 
patients receiving BBs: 2 (3.5%) and 1 (6.3%) respec-
tively, patients receiving CCBs: 3 (5.3%) and 1 (6.3%) 
respectively and patients receiving combinations of 
more than one antihypertensive drugs: 21 (36.9%) and 
1 (6.3%) respectively.
Duration of diabetes was significantly longer 
in diabetic neuropathic group than in diabetic non 
neuropathic group [14 (8.5–20) versus 4 (1.125–9.5) 
years, respectively] (p < 0.001). Drug therapy for DM 
shows no significant difference among both diabetic 
neuropathic and diabetic non neuropathic groups 
(p = 0.058). Insulin was used by 19.3% (11 patients) 
of the diabetic neuropathic group versus 50% (8 pa-
tients) of the diabetic non neuropathic group, insulin 
+ metformin was used by 54.4% (31 patients) of the 
diabetic neuropathic group versus 0% (0 patients) 
of the diabetic non neuropathic group, SU was used 
by 14% (11 patients) of the diabetic neuropathic 
group versus 25% (4 patients) of the diabetic non 
neuropathic group and SU + metformin was used 
by 14% (11 patients) of the diabetic neuropathic 
group versus 25% (4 patients) of the diabetic non 
neuropathic group. 
Painful and painless neuropathy subgroups were 
matched for age (53.709 ± 6.414, 54.153 ± 4.378 
years respectively) (p = 0.766) and sex; in the pain-
ful neuropathy subgroup [11 males (35.5%) and 20 
females (64.5%)] and in the painless neuropathy 
subgroup [15 males (57.7%) and 11 females (42.3%)] 
(p = 0.094). BMI shows no significant difference between 
both subgroups (34.69 ± 7.03 and 31.79 ± 6.15 kg/m2 
respectively) (p = 0.107). 
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Table 3. Clinical characteristics of pain in the painful neuropathy subgroup
Data (N/%)
Pain character (N/%) Pricking 3 (9.7%)
Deep aching 4 (12.9%)
Coldness 2 (6.5%)
Tingling 20 (64.5%)
Burning 2 (6.5%)
Pain severity (VAS) Median 7
Range 5–8
Pain therapy No treatment 26 (83.9%)
Carbamazepine 2 (6.5%)
Gabapentin 2 (6.5%)
Pregabalin 1 (3.2%)
Other pains No 20 (64.5%)
OA 8 (25.8%)
Frozen shoulder 1 (3.2%)
Trauma 0 (0%)
Back pain 2 (6.5%)
VAS — visual analogue scale; OA — osteoarthritis
Table 2. Demographic and clinical data of the neuropathic group
Data Subgroups p
Painful neuropathy Painless neuropathy
Age (years) Mean 53.709 54.153 0.766 
± SD 6.414 4.378
Gender (N/%) Male 11 (35.5%) 15 (57.7%) 0.094 
Female 20 (64.5%) 11 (42.3%)
BMI [kg/m2] Mean 34.69 31.79 0.107
± SD 7.03 6.15
SBP [mm Hg] Mean 125.16 136.5 0.026
± SD 15.464 19.815
DBP [mm Hg] Mean 77.42 83.46 0.049
± SD 10.318 11.981
Hypertension (N/%) Yes 21 (67.7%) 19 (73.1%) 0.774
No 10 (32.3%) 7 (26.9%)
Hypertension duration 
(years)
Median 2 6 0.411
Range 0–20 0–21
Hypertension treatment 
(N/%)
ACEIs 8 (25.8%) 6 (23.1%) 0.853
BBs 1 (3.2%) 1 (3.8%)
CCBs 2 (6.5%) 1 (3.8%)
Combination 10 (32.3%) 11 (42.3%)
No 10 (32.3%) 7 (26.9%)
DM duration (years) Median 15 11.5 0.146
Range 2–25 3.5–25
DM treatment (N/%) SU 3 (9.7%) 5 (19.2%) 0.443
Insulin 17 (54.8 %) 14 (53.5%)
Insulin + met-
formin
8 (25.8%) 3 (11.5%)
SU + metformin 3 (9.7%) 4 (15.4%)
P — probability; SD — standard deviation; BMI — body mass index; SBP — systolic blood pressure; DBP — diastolic blood pressure; ACEIs — angiotensine 
converting enzyme inhibitors; BBs — beta-blockers; CCBs — calcium channel blockers; SU — sulphonylurea
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Table 5. NDS of the neuropathic group
Data Subgroups p
Painful neuropathy Painless neuropathy
NDS: total score Mean 8.48 8.15 0.440
± SD 1.568 1.617
Vibration perception (RT) Mean 0.97 0.96 0.902
± SD 0.180 0.196
Vibration perception (LT) Mean 0.97 0.85 0.133
± SD 0.180 0.368
Temperature perception (RT) Median 1 1 0.312
Range 0–1 0–1
Temperature perception (LT) Median 1 1 0.437
Range 0–1 0–1
Pin prick (RT) Median 1 1 0.437
Range 0–1 0–1
Pin prick (LT) Median 1 1 0.054
Range 0–1 0–1
Achilles reflex (RT) Mean 1.71 1.81 0.475
± SD 0.529 0.491
Achilles reflex (LT) Mean 1.71 1.88 0.182
± SD 0.588 0.326
P — probability; SD — standard deviation; NDS — neuropathy disability score; RT — right; foot; LT — left foot
Table 4. NDS of the studied groups
Data Groups p
Diabetic neuropathy 
present
Diabetic neuropathy 
absent
Control
NDS: total score Median 8 2 0 < 0.001
Range 6–10 0–4 0–0
Vibration perception (RT) Median 1 0 0 < 0.001
Range 1–1 0–1 0–0
Vibration perception (LT) Median 1 0 0 < 0.001
Range 1–1 0–1 0–0
Temperature perception 
(RT)
Median 1 0 0 < 0.001
Range 0–1 0–0 0–0
Temperature perception 
(LT)
Median 1 0 0 < 0.001
Range 0–1 0–0 0–0
Pin prick (RT) Median 1 0 0 < 0.001
Range 1–1 0–0 0–0
Pin prick (LT) Median 1 0 0 < 0.001
Range 1–1 0–0 0–0
Achilles reflex (RT) Median 2 0 0 < 0.001
Range 1–2 0–0 0–0
Achilles reflex (LT) Median 2 0 0 < 0.001
Range 2–2 0–0 0–0
P — probability; NDS — neuropathy disability score; RT — right foot; LT — left foot 
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Table 7. Laboratory data of the neuropathic group
Data Subgroups p
Painful neuropathy Painless neuropathy
b-endorphin [pg/mL] Median 200 303 0.701
Range 26–1000 39–800
HbA1c (%) Mean 9.061 8.269 0.091
± SD 1.904 1.493
Serum creatinine [mg/dL] Mean 0.787 0.850 0.196
± SD 0.164 0.192
HDL-cholesterol [mg/dL] Mean 40.548 38.461 0.466
± SD 10.859 10.485
Total cholesterol [mg/dL] Mean 240.483 214.080 0.196
± SD 74.955 76.652
Triglycerides [mg/dL] Median 154 158 0.749
Range 69–277 66–546
LDL-cholesterol [mg/dL] Median 174 129.7 0.062
Range 72–310 52–399
P — probability; SD — standard deviation; HbA1c — glycosylated hemoglobin; HDL — high-density lipoprotein; LDL — low-density lipoprotein
Table 8. Serum b-endorphin in patients using treatment for neuropathic pain versus non-users
Data Pain treatment p
Non users Users
Median Range Median Range
b-endorphin [pg/mL] 307 14–1000 104 53–451 0.117
Table 6. Laboratory data of the studied groups
Data Groups p
Diabetic neuro-
pathy present
Diabetic neuro-
pathy absent
Control
b-endorphin [pg/mL] Median 293.00 262.50 307.00 0.275
Range 26.00–1000.00 14.00–700.00 106.00–1000.00
HbA1c (%) Mean 8.700 8.206 5.043 < 0.001
± SD 1.760 1.998 0.397
Serum creatinine [mg/dL] Mean 0.815 0.762 0.713 0.103
± SD 0.179 0.150 0.164
HDL-cholesterol [mg/dL] Median 37.00 36.50 37.00 0.998
Range 25.00–76.00 29.00–103.00 32.00–52.00
Total cholesterol [mg/dL] Median 215.00 244.50 218.00 0.453
Range 118.00–491.00 128.00–376.00 172.00–359.00
Triglycerides [mg/dL] Median 155.00 132.50 130.00 0.769
Range 66.00–546.00 73.00–232.00 71.00–238.00
LDL-cholesterol [mg/dL] Median 150.00 165.00 149.60 0.341
 Range 52.00–399.00 87.40–307.00 104.00–275.00
P — probability; SD — standard deviation; HbA1c — glycosylated hemoglobin; HDL — high-density lipoprotein; LDL — low-density lipoprotein
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Table 9. Serum b-endorphin in patients presenting with pain versus those without pain
Data Associated pain p
Absent Present
Median Range Median Range
b-endorphin [pg/mL] 283 26–1000 315 14–950 0.974
Figure 2. 0.00: patients without associated pain; 1.00: pa-
tients with associated pain
Figure 1. 0.00: patients not using treatment for neuropathic 
pain; 1.00: patients using treatment for neuropathic pain
Table 10. Serum b-endorphin in patients having different characters of pain
Data Character of pain p
Pricking Deep aching Coldness Numbness Burning
b-endorphin [pg/ml] Median 104 142 60.5 330.5 436 0.176
Range 49–680 51.7–399 26–95 53.1–1000 397–475
SBP and DBP were significantly lower in the painful 
than painless neuropathy subgroup, (125.16 ± 15.46 
and 136.5 ± 19.81 mm Hg) (p = 0.026) and (77.42 
± 10.31 and 83.46 ± 11.98 mm Hg) (p = 0.049) 
respectively. History of hypertension (HTN) wasn’t 
significantly different between both subgroups, in 
painful neuropathy subgroup; 21 patients (67.7%) were 
hypertensive while in painless neuropathy subgroup; 
19 patients (73.1%) were hypertensive (p = 0.774). 
As regard duration of HTN, there was no significant 
difference between painful and painless neuropathy 
subgroups [2 (0–20) and 6 (0–21) years respectively] 
(p = 0.411). Treatment of HTN also shows no significant 
difference; in painful neuropathy subgroup ACEIs were 
used in 8 patients (25.8%), BBs in 1 patient (3.2%), 
CCBs in 2 patients (6.5%) and combinations of more 
than one antihypertensive in 10 patients (32.3%) while 
in painless neuropathy subgroup ACEIs were used in 
6 patients (23.1%), BBs in 1 patient (3.8%), CCBs in 
1 patient (3.8%) and combinations of more than one 
antihypertensive in 11 patients (42.3%) (p = 0.853).
DM duration shows no significant difference 
between painful and painless neuropathy subgroups 
[15 (2–25) and 11.5 (3.5–25) years respectively] 
(p = 0.146). There was no significant difference regarding 
DM treatment, in painful neuropathy subgroup; SU 
were used in 9.7% (3 patients), insulin was used in 
54.8% (17 patients), insulin + metformin were used 
in 25.8% (8 patients) and SU + metformin were used 
in 9.7% (3 patients) while in painless neuropathy sub-
group; SU was used in 19.2% (5 patients), insulin was 
used in 53.5% (14 patients), insulin + metformin were 
used in 11.5% (3 patients) and SU + metformin were 
used in 15.4% (4 patients) (p = 0.443). 
The most prevalent pain character was tingling 
(64.5%), other were deep aching pain (12.9%), pricking 
pain (9.7%), coldness (6.5%) and burning (6.5%). In ad-
dition, pain severity on VAS ranges from 5 to 8. 83.9% of 
neuropathic patient were not using pain-controlling medi-
cations and 64.5%. had no other causes of chronic pain.
The neuropathy disability score (NDS) was used 
to diagnose peripheral neuropathy, total score ≥ 6 
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was diagnostic for peripheral neuropathy. Total score 
was significantly higher in diabetic neuropathic versus 
diabetic non neuropathic and control groups; [8 (6–10) 
versus 2 (0–4) and 0 (0–0%) respectively] (p < 0.001).
Vibration perception threshold score was signifi-
cantly higher in diabetic neuropathic versus diabetic non 
neuropathic and control groups; at the right foot [1 (1–1) 
versus 0 (0–1) and 0 (0–0) respectively] (p < 0.001), at 
the left foot it was the same respectively (p < 0.001). 
Temperature perception score also was significantly 
higher in diabetic neuropathic versus diabetic non neu-
ropathic and control groups; at the right foot [1 (0–1) 
versus 0 (0–0) and 0 (0–0) respectively] (p < 0.001), at 
the left foot it was the same respectively (p < 0.001).
Pin prick sensation score was significantly higher in 
diabetic neuropathic versus diabetic non neuropathic 
and control groups; at the right foot, [1 (1–1) versus 0 
(0–0) and 0 (0–0) respectively] (p < 0.001), at the left 
foot it was the same respectively (p < 0.001). Achillis 
reflex score was significantly higher in diabetic neu-
ropathic versus diabetic non neuropathic and control 
groups; at the right foot, [2 (1–2) versus 0 (0–0) and 0 
(0–0) respectively] (p < 0.001), at the left foot [2 (2–2) 
versus 0 (0–0) and 0 (0–0) respectively] (p < 0.001). 
In painful and painless neuropathy subgroups, 
NDS: total score showed no significant difference [8.48 
± 1.56 and 8.15 ± 1.61 respectively] (p = 0.440). 
With regard to vibration perception threshold score 
Table 11. Serum b-endorphin [pg/mL] in different modalities of nerve disability
Modalities of nerve disability p
Vibration perception (RT)
Intact Lost
Median 289 304.5 0.759
Range 14–1000 26–1000
Vibration perception (LT)
Intact Lost 
Median 307 284 0.817
Range 14–1000 26–1000
Temperature perception (RT)
Intact Lost 
Median 284 316 0.409
Range 14–1000 39–1000
Temperature perception (LT)
Intact Lost 
Median 284 316 0.318
Range 14–1000 51.7–1000
Pin prick (RT)
Intact Lost 
Median 301.5 239 0.453
Range 14–1000 39–1000
Pin prick (LT)
Intact Lost
Median 307 232 0.293
Range 14–1000 39–1000
Achillis reflex (RT)
Intact Intact with reinforcement Lost
Median 284 313 304.5 0.731
Range 14–1000 39–1000 26–900
Achillis reflex (LT)
Intact Intact with reinforcement Lost
Median 296 313 268.5 0.952 
Range 14–1000 44–1000 26–900
p — probability; test used — Mann-Whitney U
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there was no significant difference between painful 
and painless neuropathy subgroups; at the right foot 
it was [0.97 ± 0.18 and 0.96 ± 0.196 respectively] 
(p = 0.902), at the left foot it was [0.97 ± 0.18 and 
0.85 ± 0.368 respectively] (p = 0.133).
No significant difference between painful and 
painless neuropathy subgroups regarding temperature 
perception score; at the right foot [1 (0–1) and 1 (0–1) 
respectively] (p = 0.312), at the left foot [1 (0–1) and 
1 (0–1) respectively] (p = 0.437). Pin prick sensation 
score showed no significant difference between painful 
and painless neuropathy subgroups; at the right foot 
[1 (0–1) and 1 (0–1) respectively] (p = 0.437), at the 
left foot [1 (0–1) and 1 (0–1) respectively] (p = 0.054). 
Achillis reflex score showed no significant difference 
between painful and painless neuropathy subgroups; 
at the right foot [1.71 ± 0.529 and 1.81 ± 0.491 re-
spectively] (p = 0.475), at the left foot [1.71 ± 0.588 
and 1.88 ± 0.326 respectively] (p = 0.182).
HbA1c levels were higher in the diabetic neuropath-
ic and diabetic non neuropathic groups in comparison 
to the control group (8.700 ± 1.760, 8.206 ± 1.998 and 
5.043 ± 0.397% respectively) (p < 0.001). Serum cre-
atinine levels showed no significant difference among 
diabetic neuropathic, diabetic non neuropathic and 
control groups (0.815 ± 0.179, 0.762 ± 0.150, 0.713 
± 0.164 mg/dL respectively) (p = 0.103).
Regarding serum HDL-cholesterol and serum LDL- 
-cholesterol levels there was no significant difference 
between diabetic neuropathic, diabetic non neuropath-
ic and control groups [37 (25–76), 35.5 (29–103) and 
37 (32–52) mg/dL respectively] (p = 0.998) and [150 
(52–399), 165 (87.40–307) and 149.60 (104–275) mg/dL 
respectively] (p = 0.341).
There was no significant difference between dia-
betic neuropathic, diabetic non neuropathic and con-
trol regarding serum total cholesterol and triglycerides 
[215 (118–491), 244.5 (128–376) and 218 (172–359) 
mg/dL) respectively] (p = 0.453) and [155 (66–546), 
132.5 (73–232) and 130 (71–238) mg/dL respectively] 
(p = 0.769). 
Serum b-endorphin levels showed no significant 
difference between diabetic neuropathic, diabetic 
non neuropathic and control groups [293 (26–1000), 
262.5 (14–700) and 307 (106–1000) pg/mL respec-
tively] (p = 0.275). 
HbA1c % showed no significant difference between 
painful and painless neuropathy subgroups (9.061 ± 
1.904 and 8.269 ± 1.493% respectively) (p = 0.091). 
Painful and painless neuropathy subgroups showed 
no significant difference regarding serum creatinine 
(0.787 ± 0.164 and 0.850 ± 0.192 mg/dL respectively) 
(p = 0.196).
Serum HDL-cholesterol and LDL-cholesterol showed 
no significant difference between both painful and pain-
less neuropathy subgroups; serum HDL-cholesterol was 
(40.548 ± 10.859 and 38.461 ± 10.485 mg/dL respectively) 
(p = 0.466) and serum LDL-cholesterol was [174 (72–310) 
and 129.7 (52–399) mg/dL respectively] (p = 0.062).
In addition, there was no significant difference 
between both painful and painless neuropathy sub-
groups regarding serum total cholesterol and trigly-
cerides (240.483 ± 75 and 214.080 ± 76.652 mg/dL 
respectively) (p = 0.196) and [154 (69–277) and 158 
(66–546) mg/dL respectively] (p = 0.749) respectively. 
Serum b-endorphin shows no significant difference 
between painful and painless neuropathy subgroups 
[200 (26–1000) and 303 (39–800) pg/mL respectively] 
(p = 0.701).
Regarding serum b-endorphin there was no signifi-
cant difference between patients who used pain con-
Table 12. Correlation between serum b-endorphin and 
other variables
Data b-endorphin
r P
Severity of pain –0.097 0.371
NDS: total score 0.027 0.803
Age –0.210 0.049
BMI 0.027 0.801
DM duration 0.056 0.607
HbA1c % –0.204 0.048
Serum creatinine 0.191 0.074
NDS — neuropathy disability score; BMI — body mass index;  
HbA1c — glycosylated hemoglobin
Figure 3. Serum levels of b-endorphins according to type 
of pain
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trolling medications and those who did not use them 
[104 (53–451) and 307 (14–100) pg/mL respectively] 
(p = 0.117). There was no significant difference be-
tween diabetic neuropathic patients with or without as-
sociated pain regarding serum b-endorphin levels [315 
(14–950) and 283 (26–1000) pg/mL] (p = 0.974). There 
were no significant difference in serum b-endorphin 
levels between patients with different characters of 
pain (p = 0.176). 
There was no significant difference between lost 
and intact different modalities of nerve disability in 
either right and left foot as regard serum b-endorphin 
levels. Difference between intact and lost vibration 
perception as regard B endorphin in the right foot [289 
(14–1000) & 304.5 (26–1000) respectively] (p = 0.759), 
and in the left foot [307 (14–1000) & 284 (26–1000) 
respectively] (p = 0.817). Difference between intact 
and lost temperature perception in the right foot [284 
(14–1000) & 316 (39–1000) respectively] (p = 0.409), 
and in the left foot [284 (14–1000) & 316 (51.7–1000)
respectively] (p = 0.318). Difference between intact 
and lost pin prick sensation in the right foot [301.5 
(14–1000) & 239 (39–1000) respectively] (p = 0.453) 
and in the left foot [307 (14–1000) & 232 (39–1000) re-
spectively] (p = 0.293). Difference between intact achil-
lis reflex, intact achillis reflex with reinforcement and 
lost achillis reflex in the right foot [284 (14–1000), 313 
(39–1000), 304.5 (26–900) respectively] (p = 0.731), 
andin the left foot [296 (14–1000), 313 (44–1000) and 
268.5 (26–900) respectively] (p = 0.952).
Serum b-endorphin levels showed negative cor-
relation with age (r = –0.210, p = 0.049) and HA1c % 
(r = –0.204, p = 0.048). However, it did not correlate 
with pain severity (r = –0.097, p = 0.371), NDS: total 
score (r = 0.027, p = 0.803), BMI (r = 0.027, p = 0.801), 
s. creatinine (r = 0.191, p = 0.074) or DM duration 
(r = 0.056, p = 0.607). 
Discussion
The age of our patients ranged from 40–65 years 
and there was no significant difference regarding 
age between various groups (p = 0.053). Painful and 
painless neuropathy subgroups were also matched 
for age (p = 0.766). Age is a well defined risk factors 
for diabetic peripheral neuropathy in observational as 
well as intervention studies [11, 12]. In this work, we 
couldn’t study the effect of age as we selected all our 
patients from the age of 40 to 65 and we tried to make 
all groups matched for age.
In our study males constituted 47.7% of the total 
number of subjects included in the study and females 
constituted 52.3% and there was no significant differ-
ence between the groups regarding gender (p = 0.850). 
Painful and painless neuropathy subgroups were 
matched for sex (p = 0.094). Although female gen-
der was associated with painful DPN in some studies 
[13–15], in our study we have nearly equal distribution 
between males and females so the effect of gender 
couldn’t be assessed.
DM duration was longer in the neuropathic group 
[14 (8.2–20) years] versus the diabetic group [4 (1.125–
–9.5) years] (p < 0.001). Tesfaye et al. (2005) and Shaw 
et al. (2003) reported that diabetes duration is a well 
known risk factor for diabetic peripheral neuropathy. 
However, peripheral neuropathy was documented in 
cases with prediabetes. The pathogenic mechanisms 
of prediabetic neuropathy are multiple and not com-
pletely understood. Chronic hyperglycemia, dyslipi-
demia, microangiopathy, and factors of the metabolic 
syndrome have been implicated [16]. In painful and 
painless neuropathy subgroups, DM duration showed 
no significant difference [15 (2–25) and 11.5 (3.5–25) 
years respectively] (p = 0.146). Diabetes duration was 
found to be a correlate or predictor for painful DPN in 
some studies [15, 17] but not in others [18, 19].
There was no significant difference between vari-
ous groups regarding BMI (p = 0.489). Most of the 
subjects were obese with BMI > 30 kg/m2 which con-
stitute 68.42% of the neuropathic group, 75% of the 
diabetic group and 60% of the control group. In painful 
and painless neuropathy subgroups, BMI was (34.7 ± 
±7 kg/m2 and 31.8 ± 6 kg/m2 respectively) (p = 0.107). 
Ziegler et al. and Jambart et al., reported that obesity 
(BMI ≥ 30 kg/m2) was related to painful DPN and have 
been suggested as a risk marker [15, 18]. Also Maury 
and Brichard, suggested that obesity represents a risk 
factor for neuropathic pain as a component of the 
metabolic syndrome and as a cause of many processes 
in the pathogenesis of DPN [20].
Hypertension was associated with diabetes in 
70.2% of the neuropathic group and 56.2% of the 
diabetics without neuropathy (p = 0.295). Hyperten-
sion was reported as risk factors for diabetic peripheral 
neuropathy [11]. In our study, regarding to painful 
and painless neuropathy subgroups: there were 67.7% 
and 73.1% patients with hypertension respectively 
(p = 0.774), beside that SBP and DBP were significantly 
lower in painful neuropathy group when compared to 
painless neuropathy group (p = 0.026) (p = 0.049). 
However, hypertension was found as a risk factor for 
painful DPN in some studies [15, 17]. 
In our study, the character of pain in the painful 
neuropathy subgroup was mainly in the form of tin-
gling (64.5%), deep aching (12.9%), pricking in 9.7% 
coldness in 6.5% and burning in 6.5%. Spallone et 
al., studied 59 patients with painful DPN and found 
paresthesia and burning as the most frequent sensory 
descriptors followed by paroxysmal pain (electric shock 
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and stabbing), evoked pain (by brushing, pressure and 
cold), and deep pain (squeezing and pressure) [21]. 
Baron et al., found that the association between burn-
ing, prickling, and numbness was the most common 
pain sensory profile (26%), followed by the pattern of 
pain attacks (16%), burning with both prickling and 
allodynia without numbness (13%), and allodynia with 
hyperalgesia (9%) [22].
In our study, NDS was significantly higher in neu-
ropathic group in comparison to diabetic and control 
groups (p < 0.001), however, there were no significant 
differences between painful and painless neuropathy 
subgroups regarding all items of NDS. Veves et al., sug-
gested that neuropathic pain could be present at any 
stage of DPN, from subclinical to very late neuropathy 
[23]. Veves et al., also found that the score of sensory 
deficits was higher in patients with painful than in 
those with painless DPN [24]. Another study found that 
painful DPN patients had worse sensorimotor deficits 
in comparison to patients with nonpainful DPN [25]. 
While Boulton et al., reported that painful symptoms 
improve with the worsening of the sensory loss [26]. 
Pain in painful DPN would appear to be mainly as-
sociated with the impairment of small afferent fibers, 
however it couldn’t be confirmed that there is no small 
fiber impairment in the absence of pain [27]. Krämer 
et al., found that those with painful DPN showed no 
significant difference in vibration perception thresholds 
and thermal thresholds in comparison to those with 
painless DPN [28]. Vrethem et al., detected that tactile 
sensitivity but not thermal sensitivity were more com-
promised in diabetic patients with painful compared 
with those with painless DPN [29]. 
In our study, we found no significant difference 
regarding serum b-endorphin levels neither between 
diabetic neuropathic, diabetic non neuropathic and 
control groups (p = 0.275), or between the painful 
neuropathy subgroup and painless neuropathy sub-
group (p = 0.701).
In the literature, few studies were found to study 
b-endorphin level in patients with diabetic neuropathy. 
Cakir et al., conducted a study on 7 diabetic patients 
with painful DN, 7 diabetic patients without DN, and 
7 healthy control subjects to investigate the efficacy 
of L-carnitine (LC) in the treatment of painful diabetic 
neuropathy (DN) and its effects on levels of the endo-
genous peptide b-endorphin. They found no difference 
in basal b-endorphin levels between diabetic patients 
with painful DN and diabetic patients without neuropa-
thy and they also spotted that basal b endorphin levels 
were significantly lower in the diabetic patients in com-
parison to the control group [30]. Tsigos et al., reported 
that b-endorphin concentrations are reduced in the CSF 
of patients with sensory diabetic polyneuropathy. How-
ever the difference wasn’t statistically significant be-
tween those patients who have painful and those who 
have painless neuropathy [31]. In our study we found 
no significant correlation between b-endorphin concen-
trations and severity of pain (r = –0.097, p = 0.371). 
However, b-endorphin levels were significantly nega-
tively correlated with age (r = –0.210, p = 0.049) and 
HA1c % (r = –0.204, p = 0.048). The effect of age on 
b-endorphin level was previously suggested by Good-
win et al., who described that b-endorphin levels were 
significantly negatively correlated with age [32]. 
Serum b-endorphin levels showed no significant dif-
ference in our patients how used pain controlling medica-
tions versus those who did not use (p = 0.117). Bäckryd 
et al., found no significant correlation between CSF b 
endorphin level and use of pain medications in patients 
with chronic neuropathic pain [9]. However, Tramadol 
which is a drug with mild opiate properties had evidence 
from randomized controlled trials showing that tramadol 
is an effective treatment for neuropathic pain [33].
Serum b-endorphin levels in patients with associ-
ated pain versus those without showed no significant 
difference (p = 0.974). Serum b-endorphin in patients 
with different characters of pain showed no significant 
difference (p = 0.176). There was no significant dif-
ference between lost and intact different modalities of 
nerve disability (vibration perception, pain sensation 
and temperature perception) in either right or left foot 
as regard serum b-endorphin levels. To our knowledge, 
no previous studies addressed these topics.
The complex nature of pain pathway involving 
many pro and anti-nociceptive mediators could explain 
why b-endorphin concentration doesn’t show significant 
difference in our study. Another explanation can be that 
central changes may be not reflected peripherally also it 
may be wise to measure both pro and anti-nociceptive 
markers at the same time. This explanation is compat-
ible with the study of Veening et al., who observed 
that peripheral administration of b-endorphin does not 
necessarily induce the same effects as intra-cerebro-
ventricular administration; this suggests the existence 
of two functionally different b-endorphin systems, one 
for the central effects and one for the peripheral effects. 
They concluded that CSF-levels of b-endorphin are not 
a reflection of its peripheral levels [34]. Also Bäckryd et 
al., reported that there are probably two functionally 
different b-endorphin systems: one peripheral (release 
of b-endorphin by the pituitary into the systemic cir-
culation) and one central (synthesis in hypothalamic 
pro-opio-melanocortin (POMC) neurons) [9], with an 
intact blood-brain barrier (BBB) hinders free exchange 
of b-endorphin between plasma and CSF [35].
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In addition, short half-life of b-endorphin was re-
ported in some studies, which means that spikes for its 
serum concentration may be missed during the assay. 
Foley et al., reported that the mean terminal half-life 
after intravenous administration of 5 or 10 mg of hu-
man b-endorphin was 37 min [36]. Veening et al., also 
reported that half-life values of b-endorphin vary from 
20 to 50 min in the human circulation [34]. Butelman 
et al., reported that full-length b-endorphin was detect-
able in all subjects up to 5 minutes after intravenous 
administration [37]. Moreover, Bruehl et al., reported 
that chronic pain may initially be associated with up-
regulation of endogenous opioid analgesic systems, 
which then may become dysfunctional over time [38].
HbA1c % was significantly higher in diabetic 
neuropathic and diabetic non neuropathic groups in 
comparison to control group (8.7 ± 1.8%, 8.2 ± 2% 
and 5 ± 0.4% respectively) (p ≤ 0.001), but there was 
no significant difference between painful and painless 
neuropathy subgroups (9.061 ± 1.904% and 8.269 ± 
± 1.493% respectively) (p = 0.091). These finding is in 
accordance with Tesfaye et al., who reported that poor 
glycemic control is a risk factor for diabetic peripheral 
neuropathy [11]. However, Jin et al., reported that the 
best-known pathogenic factor of DPN is hypergly-
cemia-induced oxidative stress, and these oxidative 
stresses are worsened by acute glucose fluctuations 
[39]. Xu et al., found that glycemic variability assessed 
by continuous glucose monitoring was significantly 
independent risk factor for DPN in type 2 diabetes with 
well-controlled HbA1c % (HbA1c  <  7.0%) [40]. Oyibo 
et al., found that patients with painful neuropathy 
had greater glycemic excursions and possibly poorer 
diabetes control, compared with patients with painless 
neuropathy [41].
In our study lipid profile evaluation showed no 
significant difference between various groups. Padilla 
et al, reported that dyslipidemia is linked to diabetic 
neuropathy, and several underlying mechanisms have 
been identified, free fatty acids have been shown to 
directly cause injury to Schwann cells in vitro, and also 
have systemic effects such as promoting inflammatory 
cytokine release from adipocytes and macrophages 
[42]. Kassem et al., found that hypertriglyceridemia 
affects conduction parameters in peripheral nerves in 
a trend suggestive of early peripheral neuropathy [43]. 
In Our study, we found no significant differences 
regarding serum b-endorphin levels neither between 
diabetic neuropathic, diabetic non neuropathic and 
control groups, or between painful and painless 
neuropathy subgroups. There were no significant dif-
ferences regarding serum b-endorphin levels between 
patients with different characters of pain and there 
were no correlations to pain severity. There were no 
significant differences between lost and intact differ-
ent modalities of nerve disability with regard to serum 
b-endorphin levels. 
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